The use of XXXX in Japan: results of multicentre clinical trials.

@entity1 @entity5 @entity101 @entity6555
1 The anti- @entity101 effects and safety of @entity6555 have been evaluated in multicentre clinical trials in Japan based on unified study protocols. The results of three studies are reported. 2 A total of 178 @entity1 with essential @entity101 were treated with @entity6555 for 12 weeks, 127 of them with @entity6555 alone (monotherapy) and the other 51 with @entity6555 plus diuretics (combined therapy). 3 Satisfactory antihypertensive effects were achieved in 76 of the 119 assessable @entity1 in the monotherapy group and 25 of the 49 in the combined therapy group. The mean daily doses of @entity6555 were 329 mg in the monotherapy group and 374 mg in the combined therapy group. Seven @entity1 (six in the monotherapy group; one in the combined therapy group) were withdrawn from the trials due to side-effects. 4 Sixty-one @entity1 with @entity101 were treated with @entity6555 alone or combined with diuretics for 6 months or longer. In most of these @entity1 , good blood pressure control was achieved. No @entity1 had to discontinue the treatment due to side-effects. The mean daily doses of @entity6555 were stabilised in and after week 8 of the treatment at an average of 260 mg in the monotherapy and 450 mg in the combined therapy. Tolerance to the anti- @entity101 effect did not develop. 5 Thirty @entity1 with phaeochromocytoma were treated with @entity6555 and good blood pressure control was achieved in 21 of them. The effects of @entity6555 were better in @entity1 with predominantly adrenaline-secreting @entity5 , and better in @entity1 with sustained @entity101 type than in those with paroxysmal @entity101 type.
